| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ahmet Akyol, A Can Senel, Hülya Ulusoy, Filiz Karip, Nesrin Erciye. Delayed respiratory depression after risperidone overdose. Anesthesia and analgesia. vol 101. issue 5. 2005-11-22. PMID:16244016. |
risperidone is an atypical antipsychotic drug used for the treatment of schizophrenia. |
2005-11-22 |
2023-08-12 |
Not clear |
| Sheila Assunção, José Jiménez, Nora Pacheco, Fabiola Navarro Marún, Douglas Quintero, Isabel Aspilcueta Flores, Carlos L Pérez Desanti, Arsenio Rosado-Franco, Guillermo Tapia Paniagua, Amado Nieto Caraveo, Sergio Sanchez Cázares, Jaime Aguilar Gasca, Erick Landa Fournais, Joanna Leadbette. [Latin America: clinical responses to the antipsychotic drugs]. Vertex (Buenos Aires, Argentina). vol 16. issue 62. 2005-11-10. PMID:16077867. |
to compare the effectiveness of a 12 months antipsychotic monotherapy treatment with olanzapine, risperidone and an atypical antipsychotic drug in latin american patients with schizophrenia. |
2005-11-10 |
2023-08-12 |
Not clear |
| Gábor Falud. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 7. issue 1. 2005-11-01. PMID:16167464. |
long acting risperidone initiated during inpatient and outpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia. |
2005-11-01 |
2023-08-12 |
Not clear |
| Xinhua S Ren, Lewis E Kazis, Austin F Lee, Yu-Hui Huang, Alaa Hamed, Francesca Cunningham, Lawrence Herz, Donald R Mille. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. Schizophrenia research. vol 77. issue 2-3. 2005-10-13. PMID:15894460. |
patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. |
2005-10-13 |
2023-08-12 |
Not clear |
| Xinhua S Ren, Lewis E Kazis, Austin F Lee, Yu-Hui Huang, Alaa Hamed, Francesca Cunningham, Lawrence Herz, Donald R Mille. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. Schizophrenia research. vol 77. issue 2-3. 2005-10-13. PMID:15894460. |
in this study, we examined the association between patient characteristics and the likelihood of being initiated on olanzapine or risperidone, two of the most frequently prescribed atypical agents for schizophrenia. |
2005-10-13 |
2023-08-12 |
Not clear |
| Robert A Lasser, Cynthia A Bossie, Georges M Gharabawi, John M Kan. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophrenia research. vol 77. issue 2-3. 2005-10-13. PMID:15908183. |
remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. |
2005-10-13 |
2023-08-12 |
Not clear |
| Martin Dossenbach, Cesar Arango-Dávila, Hernan Silva Ibarra, Eric Landa, Jaime Aguilar, Osvaldo Caro, Joanna Leadbetter, Sheila Assunçã. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. The Journal of clinical psychiatry. vol 66. issue 8. 2005-10-13. PMID:16086618. |
response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the intercontinental schizophrenia outpatient health outcomes (ic-soho) study. |
2005-10-13 |
2023-08-12 |
Not clear |
| Martin Dossenbach, Cesar Arango-Dávila, Hernan Silva Ibarra, Eric Landa, Jaime Aguilar, Osvaldo Caro, Joanna Leadbetter, Sheila Assunçã. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. The Journal of clinical psychiatry. vol 66. issue 8. 2005-10-13. PMID:16086618. |
the primary aim of this study was to compare the effectiveness of 12 months' treatment with olanzapine, risperidone, quetiapine, or haloperidol in preventing relapse of schizophrenia. |
2005-10-13 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Jun Nakamura, Koji Shinkai, Makiko Goto, Yasuhisa Yamada, Kyoko Kaji, Shingo Kakihara, Nobuhisa Ueda, Kimio Kohara, Hideaki Ninomiya, Hideaki Egami, Hisao Maed. An open study of risperidone liquid in the acute phase of schizophrenia. Human psychopharmacology. vol 20. issue 4. 2005-10-04. PMID:15830401. |
an open study of risperidone liquid in the acute phase of schizophrenia. |
2005-10-04 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Jun Nakamura, Koji Shinkai, Makiko Goto, Yasuhisa Yamada, Kyoko Kaji, Shingo Kakihara, Nobuhisa Ueda, Kimio Kohara, Hideaki Ninomiya, Hideaki Egami, Hisao Maed. An open study of risperidone liquid in the acute phase of schizophrenia. Human psychopharmacology. vol 20. issue 4. 2005-10-04. PMID:15830401. |
an open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia. |
2005-10-04 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Jun Nakamura, Koji Shinkai, Makiko Goto, Yasuhisa Yamada, Kyoko Kaji, Shingo Kakihara, Nobuhisa Ueda, Kimio Kohara, Hideaki Ninomiya, Hideaki Egami, Hisao Maed. An open study of risperidone liquid in the acute phase of schizophrenia. Human psychopharmacology. vol 20. issue 4. 2005-10-04. PMID:15830401. |
eighty-eight patients (m/f: 50/38; age: 18-74 years;, mean +/- sd =32 +/- 16 years) meeting dsm-iv criteria for schizophrenia and treated with risperidone liquid (14 patients also used lorazepam) were evaluated with regard to their clinical improvement and extrapyramidal side effects using the positive and negative syndrome scale (panss) and the simpson and angus scale (sas), while plasma concentrations of hva and mhpg were analysed by hplc-ecd before and 4 weeks after risperidone liquid administration. |
2005-10-04 |
2023-08-12 |
Not clear |
| Natalie Ciliberto, Cynthia A Bossie, Ronald Urioste, Robert A Lasse. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 20. issue 4. 2005-10-04. PMID:15933481. |
lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. |
2005-10-04 |
2023-08-12 |
Not clear |
| Natalie Ciliberto, Cynthia A Bossie, Ronald Urioste, Robert A Lasse. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 20. issue 4. 2005-10-04. PMID:15933481. |
this analysis aimed to assess the relationship between race and clinical response to long-acting, injectable risperidone treatment in patients with schizophrenia or schizoaffective disorder. |
2005-10-04 |
2023-08-12 |
Not clear |
| Natalie Ciliberto, Cynthia A Bossie, Ronald Urioste, Robert A Lasse. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 20. issue 4. 2005-10-04. PMID:15933481. |
in a 12-week, randomized, double-blind study, patients with schizophrenia or schizoaffective disorder received placebo or long-acting risperidone (25, 50 or 75 mg every 2 weeks). |
2005-10-04 |
2023-08-12 |
Not clear |
| Yen Kuang Yang, Yen-Huei Tarn, Yeng Hui Tarn, Ting Ying Wang, Chia-Yih Liu, Yi-Cheng Laio, Yuan-Hwa Chou, Shin-Min Lee, Chun-Chih Che. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry and clinical neurosciences. vol 59. issue 4. 2005-09-14. PMID:16048443. |
pharmacoeconomic evaluation of schizophrenia in taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. |
2005-09-14 |
2023-08-12 |
Not clear |
| Yen Kuang Yang, Yen-Huei Tarn, Yeng Hui Tarn, Ting Ying Wang, Chia-Yih Liu, Yi-Cheng Laio, Yuan-Hwa Chou, Shin-Min Lee, Chun-Chih Che. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry and clinical neurosciences. vol 59. issue 4. 2005-09-14. PMID:16048443. |
the results showed that long-acting risperidone is more cost-effective than either olanzapine or depot haloperidol for treating schizophrenia patients whose conditions are stable and whose illness duration ranges from 1 to 5 years. |
2005-09-14 |
2023-08-12 |
Not clear |
| B M McGrath, R P Tempie. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey. Pharmacopsychiatry. vol 38. issue 4. 2005-08-26. PMID:16025416. |
the present study compares the subjective responses of patients in the stable phase of schizophrenia being treated with either olanzapine or risperidone. |
2005-08-26 |
2023-08-12 |
Not clear |
| Carmen López-Carrero, Elena Arriaza, Elena Bolaños, Antonio Ciudad, Marco Municio, José Ramos, Wout Hese. Internet in clinical research based on a pilot experience. Contemporary clinical trials. vol 26. issue 2. 2005-08-08. PMID:15837443. |
a pilot project was conducted replacing the traditional hardcopy version of the case report form for an electronic one (e-crf) and with access to internet within the naturalistic randomized clinical trial of the effectiveness of olanzapine and risperidone in the treatment of schizophrenia. |
2005-08-08 |
2023-08-12 |
Not clear |
| Hans-Jürgen Möller, Pierre-Michel Llorca, Emilio Sacchetti, Stephen D Martin, Rossella Medori, Eduard Parellad. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International clinical psychopharmacology. vol 20. issue 3. 2005-08-02. PMID:15812261. |
the maintained antipsychotic efficacy of risperidone long-acting injectable (rlai) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous antipsychotic medication. |
2005-08-02 |
2023-08-12 |
Not clear |
| William A Hargreaves, P Joseph Gibson, Joseph P Gibso. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS drugs. vol 19. issue 5. 2005-07-27. PMID:15907151. |
effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. |
2005-07-27 |
2023-08-12 |
Not clear |